Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.
Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good chance that such preparations will become available for use in the routine management of allergic disease.
Cromwell
Oliver
O
Research and Development, Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, D-21465 Reinbek, Germany. oliver.cromwell@allergopharma.de
Fiebig
Helmut
H
Suck
Roland
R
Kahlert
Helga
H
Nandy
Andreas
A
Kettner
Jens
J
Narkus
Annemie
A
D000485:Allergens / Q000276:immunology*; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D011994:Recombinant Proteins / Q000276:immunology*; D014612:Vaccines / Q000276:immunology*
D000485:Allergens; D011994:Recombinant Proteins; D014612:Vaccines